The positive trend continues – stable organic sales growth in all business areas and regions

Getinge Q2 2025 Mattias Perjos, CEO Agneta Palmér, CFO



Key pillars for Getinge's profitable growth journey

Development for strategic KPIs



Improvements should be achieved through balanced leverage² and attractive long-term Return on Invested Capital³

Sales share in R12 figures. ¹⁾ Defined as products with adjusted gross margin higher than its Business Area in 2024; ²⁾ Net debt/adj. EBITDA < 2.5; ³⁾ ROIC at least > Weighted Average Cost of Capital Getinge | Presentation | Q2 Report 2025 July 18, 2025

GETINGE 🗱

Key takeaways Q2 2025

- Net sales grew by 4.1% organically and order intake increased by 4.4% organically
- Margins positively impacted by acquisitions, price and mix
- The financial position remains solid





Key activities and events Q2 2025

Offering and customers

- First Vasoview Hemopro 3 clinical cases successfully conducted in the U.S. Deliveries at a larger scale is expected to start in September
- Extension of the Servo-c ventilator with a neonatal option in targeted markets
- Paragonix celebrated its 100th kidney transplant case with the KidneyVault[™]
- Launched the heavy-duty Ultima 1600 LXP/HE-HD washer
- Entered a partnership with Zimmer Biomet to support Orthopaedic Ambulatory Surgery Centers (ASC) in the US
- Ramping up the XEN chemistry portfolio in the U.S. leveraging the Quadralene offering through Healthmark

Sustainability and Quality

- Complete Intra-Aortic Balloon catheter portfolio obtained EU MDR certificate
- Positive trend in regulatory compliance (findings per audit) and field corrections (field corrections per MSEK net sales)
- Online training of customers continues to increase
- CO2 emissions continue to decrease





GETINGE 🗱

Solid organic growth in Orders and Net Sales in all regions

Order Intake and Net Sales Bridge Q2 2024 – Q2 2025

Order Intake



Net Sales



GETINGE 🛠

Margins increased in the quarter despite headwinds from tariffs and FX

Adjusted Gross Profit and EBITA Bridge Q2 2024 – Q2 2025

Adjusted Gross Profit



Adjusted EBITA



Tariffs having a material impact on adjusted EBITA Impact from tariffs in Q2

Reminder from the Q1 presentation



Impact on adj EBITA in Q2 2025



Restatement: With current tariff levels, Getinge expects to reach the target of >12% average annual growth in adjusted EPS 2024-2028



Ongoing efforts to mitigate negative impact from tariffs

Working in parallel tracks with different characteristics and effects



Short-medium time to implement Medium impact Medium-long time to implement High impact



Getinge has a solid financial position

Improved FCF Y-o-Y and good safety margin on leverage despite significant acquisition

FCF positively impacted by changes in receivables ...



... and leverage continues to be way below 2.5x



GETINGE 🗱

Free Cash Flow, SEK B

Net debt/Adj EBITDA R12

Outlook 2025

Net sales for 2025 expected to increase by 2-5% organically



Summary



Key takeaways Summary Q2 2025

- Solid organic growth
- Improved margins despite tariffs and negative FX
- The financial position remains solid
- Outlook for 2025: organic net sales growth of 2-5%









Thank you



Forward looking information

This document contains forward-looking information based on the current expectations of the Getinge's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.





PASSION FOR LIFE